Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-01-04
2011-01-04
Szperka, Michael (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C436S506000
Reexamination Certificate
active
07863009
ABSTRACT:
Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, are described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are also described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified.
REFERENCES:
patent: 5175087 (1992-12-01), Ranby et al.
patent: 5968759 (1999-10-01), Roemisch et al.
patent: 6528299 (2003-03-01), Roemisch et al.
patent: 6670455 (2003-12-01), Roemisch et al.
patent: 6677440 (2004-01-01), Roemisch et al.
patent: 6911334 (2005-06-01), Roemisch et al.
patent: 7153679 (2006-12-01), Kiechl et al.
patent: 2002/0110552 (2002-08-01), Roemisch et al.
patent: 2003/0077271 (2003-04-01), Roemisch et al.
patent: 2003/0124622 (2003-07-01), Roemisch et al.
patent: 2003/0215447 (2003-11-01), Roemisch et al.
patent: 2004/0063187 (2004-04-01), Roemisch et al.
patent: 2004/0186277 (2004-09-01), Roemisch et al.
patent: 2005/0202002 (2005-09-01), Roemisch et al.
patent: 2 311 479 (2000-10-01), None
patent: 199 26 531.3 (1999-06-01), None
patent: 199 03 693 (1999-10-01), None
patent: 100 23 923 (2000-12-01), None
patent: 199 37 218 (2001-02-01), None
patent: 199 37 219 (2001-02-01), None
patent: 100 36 641.4 (2002-02-01), None
patent: 0 952 215 (1999-10-01), None
patent: 1 033 405 (2000-09-01), None
patent: 1 059 359 (2000-12-01), None
patent: 1 074 615 (2001-02-01), None
patent: 1 074 616 (2001-02-01), None
patent: 1 182 258 (2002-02-01), None
Campbell, A. , Monoclonal Antibody Technology, 1984, Elsevier Science Publishers B.V., pp. 1-32.
Goding, James W. Monoclonal Antibodies:Principles and Practice, 1983, Academic Press, pp. 56-97.
N. H.-Choi-Miura, et al. “Purification and Characterization of a Novel Hyaluronan-Binding Protein (PHBP) from Human Plasma: It Has Three EGF, a Kringle and a Serine Protease Domain, Similar to Hepatocyte Growth Factor Activator”J. Biochem., 119(6):1157-65 (1996).
A. Hunfeld, et al. “Identification of the Thrombin-Like Activity of PCCs”Annals of Hematology, (76 Suppl. 1):A101 (1998).
A. Hunfeld, et al. “Detection of a Novel Plasma Serine Protease During Purification of Vitamin K-dependent Coagulation Factors”FEBS Letters, 456:290-94 (1999).
J. Römisch, et al. “A Protease Isolated from Plasma which Activiates FVII in a Tissue Factor Independent Manner but Inactivates FV and FVIII”Annals of Hematology, (78 Suppl. 1):A10 (1999).
J. Römisch, et al. “The FVII Activating Protease Mediates Fibrinolytic Effects Activating Single-Chain Plasminogen Activators”Annals of Hematology, (78 Suppl. 1):A24 (1999).
J. Römisch, et al. “A Protease Isolated from Human Plasma Activating Factor VII Independent of Tissue Factor”Blood Coagul. Fibrinol., 10:471-479 (1999).
J. Römisch, et al. “The FVII Activating Protease Cleaves Single-Chain Plasminogen Activators”Haemostasis, (29):292-299 (1999).
J. Römisch et al., “Quantitation of the Factor VII- and Single Chain Plasminogen Activator-Activating Protease in Plasmas of Healthy Subjects,”Blood Coagulation and Fibrinolysis,12(5):375-383 (2001).
N.-H. Choi-Miura et al., “Proteolytic Activation and Inactivation of the Serine Protease Activity of Plasma Hyaluronan Binding Protein,”Biol. Pharm. Bull., 24(5):448-452 (2001).
J. Willeit et al., “Marburg I Polymorphism of Factor VII-Activating Protease: A Prominent Risk Predictor of Carotid Stenosis,”Circulation, 107(5):667-670 (2003).
J. Römisch “Factor VII Activating Protease (FSAP): A Novel Protease in Hemostasis,”Biol. Chem., 383:1119-1124 (2002).
J. Römisch et al., “The FrequentMarburg IPolymorphism Impairs the Pro-Urokinase Activating Potency of the Factor VII Activating Protease (FSAP),”Blood Coagulation and Fibrinolysis,13(5):433-441 (2002).
Kitamura (Mar. 29, 1995) GenBank accession D49742.
K. Laake et al., “Activation of Purified Plasma Factor VII by Human Plasmin, Plasma Kallikrein, And Activated Components of the Human Intrinsic Blood Coagulation System,”Thrombosis Research, vol. 5 (6): 759-772 (1974).
K. Hashimoto et al., “Cloning of the cDNA for a Mouse Homologue of Human PHBP: A Novel Hyaluronan-Binding Protein,”Biol. Pharm. Bulletin, vol. 20(11): 1127-1130 (1997).
J-I. Sumiya et al., “Isolation and Characterization of the Plasma Hyaluronan-Binding Protein (PHBP) Gene (HABP2),”J. Biochem., vol. 122: 983-990 (1997).
M. Etscheid et al., “Characterization of a Novel Serine Protease From Plasma,” (1999) (Abstract).
A. Vostrov et al., “Plasma Hyaluronan-binding Protein Is a Serine Protease,”J. Biological Chemistry, vol. 275 (30): 22978-22985 (2000).
T. Prins et al., “Cloning and characterization of a glutathione S-transferase homologue from the plant pathogenic fungusBoyrytis cineria,” Molecular Plant Pathology, 1:169-178 (2000).
P.M. Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,”Research in Immunology, 145:33-36 (1994).
M. Etscheid et al., “Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism,”Biol. Chem. 381:1223-1231 (2000).
Harlow et al., “Antibodies, A Laboratory Manual,” Cold Spring Harbor Laboratories, pp. vi and 319-358 (1988).
C. Janeway et al., “Immunobiology,” 3rded., Garland Publishing, Inc., pp. 2:8-2:11 (1997).
Rose et al., “Manual of Clinical Immunology,” 5thed., pp. 21-22 (1997).
F. Hofman, “Immunohistochemistry,” inCurrent Protocols in Immunology, John Wiley & Sons, Inc., pp. 5.8.1-5.8.22 (1996).
Gallagher et al., “Immunoblotting and Immunodetection,” inCurrent Protocols in Immunology, John Wiley & Sons, Inc., pp. 8.10.1-8.10.21 (1998).
Becker Margret
Feussner Annette
Knoblauch Bernd
Lang Wiegand
Muth-Naumann Gudrun
CSL Behring GmbH
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Szperka Michael
LandOfFree
Mutants of the factor VII-activating protease and detection... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutants of the factor VII-activating protease and detection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutants of the factor VII-activating protease and detection... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741648